Recent Trends of Infliximab Treatment for Crohn’s Disease
김미진, 최연호,
소속 상세정보
김미진 ( Kim Mi-Jin )
성균관대학교 의과대학 삼성서울병원 소아과학교실
최연호 ( Choe Yon-Ho )
성균관대학교 의과대학 삼성서울병원 소아과학교실
KMID : 0816120120150010019
Abstract
Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract and characterized by relapsing and remitting episodes, with progression over time to complications of stricture, fistulas, or abscesses. The etiology is unknown, although the common opinion is that the disease arises from a disordered immune response to the gut contents in genetically predisposed individuals. Infliximab is a mouse-human chimeric antibody against tumor necrosis factor a, and has proven to be effective in active Crohn’s disease for both induction and maintenance therapy. Despite the growing experience with infliximab in Crohn’s disease, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of infliximab in Crohn’s disease and to discuss the yet-unsolved issues.
키워드
Crohn’s disease; Infliximab
원문 및 링크아웃 정보
등재저널 정보